Drugs / HRYZ-T101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05952947 | Nov 2023 → Dec 2027 expected | anal carcinoma, cervical cancer, head and neck squamous cell carcinoma, penile carcinoma +2 | HRYZ Biotech Co. | Recruiting | No outcome recorded |
| Phase 1 | NCT05787535 | Mar 2023 → Feb 2025 | anal carcinoma, cervical cancer, head and neck squamous cell carcinoma, oropharyngeal carcinoma +3 | HRYZ Biotech Co. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRYZ-T101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05787535 ↗ |
| Modality | Cell therapy | “TCR-T cell” NCT05787535 ↗ |
| Route | Intravenous | “the TCR-T cells will be administered intravenously” NCT05952947 ↗ |